Citations Appearing in 2010

  1. Aarons, L. and K. Ogungbenro. Optimal design of pharmacokinetic studies. Basic and Clinical Pharmacology and Toxicology 106(3):250-255, 2010.
  2. Abraham, A.K., L. Kagan, S. Kumar, and D.E. Mager. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-B in mice. Journal of Pharmacology and Experimental Therapeutics 334(1): 327-332, 2010.
  3. Acosta, E.P., and D.W. Kimberlin. Determination of appropriate dosing of influenza drugs in pediatric patients. Clinical Pharmacology and Therapeutics 88(5): 704-707, 2010.
  4. Adane, E., Z. Liu, T.-X. Xiang, B. Anderson, and M. Leggas. Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67. Pharmaceutical Research 27(7): 1416-1425, 2010.
  5. Ait-Oudhia, S., J.-M. Scherrmann, and W. Krzyzanski. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple Iintravenous dosing in rats. Journal of Pharmacology and Experimental Therapeutics 334(3):897-910, 2010.
  6. Anderson, B.J. and N.H.G. Holford. Leaving no stone unturned, or extracting blood from stone? Pediatric Anesthesia 20(1):1-6, 2010.
  7. Ariano, R.E., D.S. Sitar, S.A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Canadian Medical Association Journal 182(4):357-363, 2010.
  8. Beaty, O., S. Berg, S. Blaney, M. Malogolowkin, M. Krailo, R. Knight, P. Schaiquevich, C. Stewart, Z. Chen, M. Nelson, S. Voss, S.P. Ivy, and P.C. Adamson. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children’s Oncology Group study. Pediatric Blood and Cancer 55(3):440-445, 2010.
  9. Benkali, K., L. Rostaing, A. Premaud, lie, J.-B. Woillard, F. Saint-Marcoux, S. Urien, N. Kamar, P. Marquet, and A. Rousseau. Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clinical Pharmacokinetics 49(10):683-692, 2010.
  10. Bhavnani, S.M., C.M. Rubino, P.G. Ambrose, and G.L. Drusano. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clinical Infectious Diseases 50(12):1568–1574, 2010.
  11. Brown, A., J.J. McSharry, Q. Weng, E.M. Driebe, D.M. Engelthaler, K. Sheff, P.S. Keim, J. Nguyen, and G.L. Drusano. An in vitro system for modeling influenza a virus resistance under drug pressure. Antimicrobial Agents and Chemotherapy 54(8):3442-3450, 2010.
  12. Buitrago, E., C. Höcht, G. Chantada, A. Fandiño, E. Navo, D.H. Abramson, P. Schaiquevich, and G.F. Bramuglia. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. Experimental Eye Research 91(1):9-14, 2010.
  13. Bulitta, J.B., M. Kinzig, V. Jakob, U. Holzgrabe, F. Sörgel, and N.H.G. Holford. Nonlinear pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage regimens. British Journal of Clinical Pharmacology 70(5):682-693,2010.
  14. Bulitta, Jürgen B., J.C. Yang, L. Yohonn, N.S. Ly, S.V. Brown, R.E. D’Hondt, W.J. Jusko, A. Forrest, and B.T. Tsuj. Attenuation of colistin bactericidal activity by high inoculum of pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrobial Agents and Chemotherapy 54(5):2051-2062, 2010.
  15. Carcaboso, A.M., M.A. Elmeliegy, J. Shen, S.J. Juel, Z.M. Zhang, C. Calabrese, L. Tracey, C.M. Waters, and C.F. Stewart. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Research 70(11):4499-4508, 2010.
  16. Chevillard, L., B. Mégarbane, F.J. Baud, P. Risède, X. Declèves, D. Mager, . . .and I. Ricordel. PRECLINICAL STUDY: mechanisms of respiratory insufficiency induced by methadone overdose in rats. Addiction Biology 15(1):62-80, 2010.
  17. Clausen, D.M., J. Guo, R.A. Parise, J.H. Beumer, M.J. Egorin, J.S. Lazo, E.V. Prochownik, and J.L. Eiseman. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. Journal of Pharmacology and Experimental Therapeutics 335(3):715-727, 2010.
  18. Decker, B.S., M.B. Kays, M. Chambers, M.A. Kraus, S.M. Moe, and K.M. Sowinski. Vancomycin Pharmacokinetics and Pharmacodynamics during Short Daily Hemodialysis. Clinical Journal of the American Society of Nephrology 5(11):1981-1987, 2010.
  19. Della Torre, M., J.U. Hibbard, H. Jeong, and J.H. Fischer. Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. American Journal of Obstetrics and Gynecology 203(3):254.251-254, 2010.
  20. Deshpande, D., S. Srivastava, C. Meek, R. Leff, G.S. Hall, and T. Gumbo. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated mycobacterium avium infection. Antimicrobial Agents and Chemotherapy 54(6):2534-2539, 2010.
  21. Deshpande, D., S. Srivastava, C. Meek, R. Leff, and T. Gumbo. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular mycobacterium avium. Antimicrobial Agents and Chemotherapy 54(5):1728-1733, 2010.
  22. Di Verniero, C.A., F. Bertera, F. Buontempo, E. Bernabeu, D. Chiappetta, M.A. Mayer, G.F. Bramuglia, C.A. Taira, and C. Höcht. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a NG-nitro-l-arginine methyl ester rat model of secondary hypertension. Journal of Pharmacy and Pharmacology 62(7):890-900, 2010.
  23. Dirks, N.L. and B. Meibohm. Population pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics 49(10):633-659, 2010.
  24. Drusano, G.L., N. Sgambati, A. Eichas, D.L. Brown, R. Kulawy, and A. Louie. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio 1(3):e00139-00110, 2010.
  25. Fouladi, M., C.F. Stewart, S.M. Blaney, A. Onar-Thomas, P. Schaiquevich, R.J. Packer, A. Gajjar, L.E. Kun, J.M. Boyett, and R.J. Gilbertson. Phase I trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology 28(27):4221-4227, 2010.
  26. Gérard, C., N. Bleyzac, P. Girard, G. Freyer, Y. Bertran, and M. Tod. Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model. Pharmaceutical Research 27(12):2602-2613, 2010.
  27. Geyer, J.R., C.F. Stewart, M. Kocak, A. Broniscer, P. Phillips, J.G. Douglas, . . .and J.M. Boyett. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. European Journal of Cancer 46(18):3287-3293, 2010.
  28. Ghoshal, S., I. Rao, J. Earp, W. Jusko, and M. Wetzler. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemotherapy and Pharmacology 66(4):681-689, 2010.
  29. Gumbo, T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial Agents and Chemotherapy 54(4):1484-1491, 2010.
  30. Hope, W.W., V. Petraitis, R. Petraitiene, T. Aghamolla, J. Bacher and T.J. Walsh. The initial 96-hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3)-{beta}-D-glucan and the consequences of delayed antifungal therapy. Antimicrobial Agents and Chemotherapy 54(11):4879-4886, 2010.
  31. Hope, W.W., P.B.Smith, A. Arrieta, D.N. Buell, M. Roy, A. Kaibara, T.J. Walsh, M. Cohen-Wolkowiez, and D.K. Benjamin Jr. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrobial Agents and Chemotherapy 54(6):2633-2637, 2010.
  32. Houzé, P., D.E. Mager, P. Risède, and F.J. Baud. Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicological Sciences 116(2):660-672, 2010.
  33. Inaba, H., C.F. Stewart, K.R. Crews, S. Yang, S. Pounds, C.H. Pui, J.E. Rubnitz, B.I. Razzouk, and R.C. Ribeiro. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer 116(1):98-105, 2010.
  34. Janzen, T., A. Giussani, C. Canzi, P. Gerundini, U. Oeh, and C. Hoeschen. Investigation of biokinetics of radioiodine with a population kinetics approach.Radiation Protection Dosimetry 139(1-3):232-235, 2010.
  35. Jelliffe, R.W. Nonparametric population modeling and bayesian analysis.Pharmacological Research 63(3): 216-224, 2010.
  36. Kagan, L., A. Abraham, J. Harrold, and D. Mager. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.Pharmaceutical Research 27(5):920-932, 2010.
  37. Kebriaei, P., T. Madden, R. Kazerooni, X. Wang, P. Thall, C. Ledesma, Y. Nieto, E.J. Shpall, C. Hosing, M. Qazilbash, U. Popat, I. Khouri, R.E. Champlin, R.B. Jones, and B.S. Andersson. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biology of Blood and Marrow Transplantation 17(3):412-420, 2010.
  38. Kenanova, V.E., T. Olafsen, F.B. Salazar, L.E. Williams, S. Knowles, and A.M. Wu. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Engineering Design and Selection 23(10):789-798, 2010.
  39. Khatri, A., J. Fisher, and M. Kirstein. Enhanced sensitivity method for measuring gemcitabine in human plasma. Chromatographia 72(9):1005-1008, 2010.
  40. Kim, Y., K. Park, and W. Kang. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. Biopharmaceutics & Drug Disposition 31(8-9):443-449, 2010.
  41. Lee, L.S., M. Kinzig-Schippers, A.N. Nafziger, L. Ma, F. Sörgel, R.N. Jones, . . .and J.S. Bertino Jr. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by monte carlo simulation. Diagnostic Microbiology and Infectious Disease 68(3):251-258, 2010.
  42. Lestner, J.M., S.J. Howard, J. Goodwin, L. Gregson, J. Majithiya, T.J. Walsh, G.M. Jensen, and W.W. Hope. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 54(8):3432-3441, 2010.
  43. Louie, A., A. Bied, C. Fregeau. B. Van Scoy, D. Brown, W. Liu, K. Bush, A. Queenan, B. Morrow, M. Khashab, J.B. Kahn, S. Nicholson, R. Kulawy, and G.L. Drusano. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrobial Agents and Chemotherapy54(6):2638-2645, 2010.
  44. Louie, A., C. Grasso, N. Bahniuk, B. VanScoy, D.L. Brown, R. Kulawy, and G.L. Drusano. The combination of meropenem and levofloxacin is synergistic with respect to both pseudomonas aeruginosa kill rate and resistance suppression. Antimicrobial Agents and Chemotherapy 54(6):2646-2654, 2010.
  45. Muscal, J.A., P. A. Thompson, V.L. Giranda, B.D. Dayton, J. Bauch, T. Horton, L. McGuffey, J.G. Nuchtern, R.C. Dauser, B.W. Gibson, S.M. Blaney, and J.M. Su. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemotherapy and Pharmacology 65(3):419-425, 2010.
  46. Ng, C.M., S. Bai, C.H. Takimoto, M.T. Tang, and A.W. Tolcher. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemotherapy and Pharmacology 65(2):207-217, 2010.
  47. Panetta, J.C., A. Sparreboom, C.-H. Pui, M.V. Relling, and W.E. Evan. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 6(12):e1001019, 2010.
  48. Pasipanodya, J.G. and T. Gumbo. Clinical and toxicodynamic evidence that high dose pyrazinamide is not more hepatotoxic than current low doses. Antimicrobial Agents and Chemotherapy 54(7):2847-2854, 2010.
  49. Patel, N., M.H. Scheetz, G.L. Drusano, and T.P. Lodise. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrobial Agents and Chemotherapy 54(1):460-465, 2010.
  50. Patel, N., M.H. Scheetz, G.L. Drusano, and T.P. Lodise. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. Journal of Antimicrobial Chemotherapy 65(11):2285-2290, 2010.
  51. Parker, R.S. and G. Clermont. Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges. Journal of the Royal Society Interface 7(48):989-1013, 2010.
  52. Rubino, C.M., A. Forrest, S.M. Bhavnani, G. Dukart, A. Cooper, J. Korth-Bradley, and P.G. Ambrose. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrobial Agents and Chemotherapy 54(12):5180-5186, 2010.
  53. Salinger, D.H., P. Vicini, D.K. Blough, P.V. O’Donnell, M.A. Pawlikowski, and J.S. McCune. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. The Journal of Clinical Pharmacology 50(11):1292-1300, 2010.
  54. Schneider, B., G. Kalemkerian, D. Bradley, D. Smith, M. Egorin, S. Daignault, . . .and M. Hussain. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investigational New Drugs 30(1):249-257, 2010.
  55. Shin, B.S., S. W. Hwang, J.B. Bulitta, J.B. Lee, S.D. Yang, J.S. Park, . . .and S.D. Yoo. Assessment of bisphenol a exposure in korean pregnant women by physiologically based pharmacokinetic modeling. Journal of Toxicology and Environmental Health, Part A. Current Issues 73(21):1586-1598, 2010.
  56. Singh, R., K.R. Ledesma, K.-T. Chang, and V.H. Tam. The impact of recA on levofloxacin exposure-related resistance development. Antimicrobial Agents and Chemotherapy 54(10):4262-4268, 2010.
  57. Stepensky, D. Use of unbound volumes of drug distribution in pharmacokinetic calculations. European Journal of Pharmaceutical Sciences 42(1-2):91-98, 2010
  58. Thiessen, B., C. Stewart, M. Tsao, S. Kamel-Reid, P. Schaiquevich, W. Mason, J. Easaw, K. Belanger, P. Forsyth, L. McIntosh, and E. Eisenhauer. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology 65(2):353-361, 2010.
  59. Urva, S.R., V.C. Yang, and J.P. Balthasar. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. Journal of Pharmaceutical Sciences 99(3):1582-1600, 2010.
  60. Vallance, K., W. Liu, B.N. Mandrell, J.C. Panetta, J.S. Gattuso, M. Hockenberry, S. Zupanec, L. Yang, J. Yang and P.S. Hinds. Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for all. European Journal of Cancer 46(10):1848-1855, 2010.
  61. Vázquez, H., A. Chávez-Haro, W. García-Ubbelohde, J. Paniagua-Solís, A. Alagón, and C. Sevcik. Pharmacokinetics of a F(ab’)2 scorpion antivenom administered intramuscularly in healthy human volunteers. International Immunopharmacology 10(11):1318-1324, 2010.
  62. Weiss, M., P. Li, and M. Roberts. An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: evidence for two functionally different uptake systems and saturable binding. Pharmaceutical Research 27(9):1999-2007, 2010.
  63. Xiao, J., W. Krzyzanski, Y.-M. Wang, H. Li, M. Rose, M. Ma, Y. Wu, B. Hinkle, and J. Perez-Ruixo. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. The AAPS Journal 12(4):646-657, 2010.
  64. Yang, J., D.E. Mager, and R.M. Straubinger. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. The American Association of Pharmaceutical Scientists Journal 12(10):1-10, 2010.
  65. Zhang, L., C.M. Ng, J.F. List, and M. Pfister. Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism-Based Model Characterizing Sodium-Glucose Cotransporter-2 Inhibition. The Journal of Clinical Pharmacology 50(9 ):113S-120S, 2010.
  66. Zhang, Q., Y. Tao, Y. Zhu, and D. Zhu. Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. Clinical Therapeutics 32(1):171-178, 2010.
  67. Zhou, Q., Z. Zheng, B. Xia, L. Tang, C. Lv, W. Liu, . . .and M. Hu. Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin a by human liver and intestinal microsomes. Pharmaceutical Research 86(5):519-526, 2010.